Search by conditions:


Protocol Description Phase
14-135 A Dose-Finding Phase 1 Study of TAS-120 in Patients with Advanced Solid Tumors with or without Fibroblast Growth Factor/Receptor(FGF/FGFR)- Related Abnormalities Followed by a Phase 2 Study in Patients with Advanced Solid Tumors or Multiple Myeloma FGF/FGFR-Related Abnormalities  (View details on Phase II
15-497 A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors  (View details on Phase II
15-577 A Phase 1, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KTN0158 in Adult Patients with KIT Positive Advanced Solid Tumors  (View details on Phase I
16-395 A Phase 1b Study to Evaluate TAK-659 in Combination With Nivolumab in Patients With Advanced Solid Tumors  (View details on Phase I
12-487 A Phase I Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (BMS-986015) Administered in Combination with Anti-PD-1 (BMS-936558) in Advanced Refractory Solid Tumors  (View details on Phase I
13-251 A Phase I, Gene Alteration-based, Open Label, Multicenter Study of Oral Debio 1347 (CH5183284) in Patients With Advanced Solid Malignancies, Whose Tumours Have an Alteration of the Fibroblast Growth Factor Receptor (FGFR) 1, 2 or 3 Genes  (View details on Phase I
10-308 A Phase II Study Of Proton Beam Therapy For Locally Advanced Sinonasal Malignancies  (View details on Phase II
16-200 An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)  (View details on Phase II
12-267 Phase I Study of Afatinib with Postoperative Radiation Therapy for Intermediate and High Risk Squamous Cancer of the Head and Neck (SCCHN)  (View details on Phase I
15-185 Randomized Phase II Study Comparing Selumetinib to Placebo for Enhancing the Clinical Efficacy of Radioactive Iodine (RAI) for RAI-Avid Recurrent/Metastatic Thyroid Cancers Uptake  (View details on Phase II
15-469 Study of Anti-PD-1 Therapy for HPV-associated Recurrent Respiratory Papilloma Patients with Laryngeal, Tracheal and/or Pulmonary Involvement  (View details on Phase II
11 clinical trials listed

Back to Top